科研动态PubMed 摘要

艾加莫德治疗全身型重症肌无力的安全性和有效性:一项系统评价和荟萃分析。

PubMed 白名单日捞 · 2026-01-01

完整摘要 · 中文译文

背景:严重肌无力是全身型肌无力(gMG)的标志性特征,这是一种严重降低生活质量的慢性自身免疫性疾病。传统免疫抑制治疗可能具有显著的不良反应,且仅能部分缓解症状。临床试验已证明艾加莫德(efgartigimod)的潜力,这是一种新生儿Fc受体(FcRn)拮抗剂,可降低有害的IgG自身抗体。本系统综述与荟萃分析评估了其疗效和安全性,将随机对照证据与非对照真实世界证据分别进行分析。 方法:截至2025年8月,我们对PubMed、Scopus和Web of Science进行了全面检索,并以Cochrane对照试验中心注册库(CENTRAL)和ClinicalTrials.gov作为补充,检索评估艾加莫德治疗gMG的观察性研究和随机对照试验(RCT)。主要结局为重症肌无力日常生活活动能力(MG-ADL)改善、应答率、不良事件和定量重症肌无力(QMG)评分。安慰剂对照RCT采用双臂荟萃分析进行合并(主要证据),非对照队列研究和病例系列采用单臂荟萃分析进行合并(支持性证据),使用Review Manager 5.4和R(v4.4.2)中的随机效应模型。进行了敏感性分析、留一法影响分析和亚组分析,计算了单臂结局的95%预测区间,并采用推荐意见分级的评估、制定与评价(GRADE)方法对证据确定性进行评级。本综述已retr 已分别在前瞻性注册系统PROSPERO注册(CRD420261518373)。 结果:我们纳入了11项研究(2项随机对照试验、6项队列研究和3项病例系列),共480名参与者(385名接受艾加莫德治疗,95名接受安慰剂治疗)。在随机对照试验中,艾加莫德在效应峰值时改善了MG-ADL(平均差[MD] = -2.62,95%置信区间:-3.99至-1.25,p = 0.0002)和QMG评分(MD = -4.59,95%置信区间:-6.24至-2.94,p < 0.00001),但在随访结束时差异不显著。艾加莫德组的MG-ADL应答者频率高于安慰剂组(风险比[RR] = 1.90,95%置信区间:1.40-2.56,p < 0.0001),包括在乙酰胆碱受体(AChR)抗体阳性患者中(RR = 2.37,95%置信区间:1.61-3.47,p < 0.0001)。不良事件发生率与安慰剂无差异(RR = 0.93,95%置信区间:0.81-1.07,p = 0.29)。效应峰值、应答者和安全性结局的证据确定性为中等。在非对照真实世界研究中,AChR抗体阳性和肌肉特异性酪氨酸激酶(MuSK)抗体阳性患者中观察到应答(MuSK抗体阳性合并比例 = 0.781,95%置信区间:0.499-0.927;18名患者),且皮质类固醇剂量减少,但该证据的确定性极低。单臂估计显示中至相当大的异质性(I2高达98.8%)和较宽的95%预测区间,尽管每项纳入研究均显示MG-ADL改善和皮质类固醇剂量减少。当限制于3期ADAPT试验(该试验贡献了71%-92%的统计权重)时,随机化估计值未发生变化。 结论:在随机试验中,艾加莫德产生临床 在全身型重症肌无力(gMG)中具有有意义的短期改善,且不良事件发生率与安慰剂相当。由于获益在随访结束时未能维持,可能需要周期性、个体化的再治疗。真实世界数据提示在多种血清学亚型中均有获益,并具有减少皮质类固醇用量的效应;然而,这些非对照估计异质性较大且证据确定性极低,仍需更大规模、更长期的对照研究(最好由非生产商独立开展)来证实这些发现。

完整摘要 · 英文原文

BACKGROUND: Severe muscle weakness is a hallmark of generalized myasthenia gravis (gMG), a chronic autoimmune disease that severely reduces quality of life. Traditional immunosuppressive treatments can have significant adverse effects and only partially relieve symptoms. Clinical trials have demonstrated the potential of efgartigimod, a neonatal Fc receptor (FcRn) antagonist that lowers harmful IgG autoantibodies. This systematic review and meta-analysis assessed its efficacy and safety, analyzing randomized controlled evidence separately from uncontrolled real-world evidence. METHODS: Up until August 2025, we conducted a thorough search of PubMed, Scopus, and Web of Science, supplemented by the Cochrane Central Register of Controlled Trials (CENTRAL) and ClinicalTrials.gov, for observational studies and randomized controlled trials (RCTs) evaluating efgartigimod in gMG. Improvement in myasthenia gravis activities of daily living (MG-ADL), responder rates, adverse events, and quantitative myasthenia gravis (QMG) scores were the main outcomes. Placebo-controlled RCTs were pooled in two-arm meta-analyses (primary evidence) and uncontrolled cohort studies and case series in single-arm meta-analyses (supportive evidence), using random-effects models in Review Manager 5.4 and R (v4.4.2). Sensitivity, leave-one-out influence, and subgroup analyses were performed, 95% prediction intervals were calculated for single-arm outcomes, and the certainty of evidence was rated using the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) approach. The review was retrospectively registered in PROSPERO (CRD420261518373). RESULTS: We included 11 studies (two RCTs, six cohort studies, and three case series) comprising 480 participants (385 efgartigimod-treated and 95 placebo-treated). In the RCTs, efgartigimod improved MG-ADL (mean differences [MD] = -2.62, 95% CI: -3.99 to -1.25, p = 0.0002) and QMG scores (MD = -4.59, 95% CI: -6.24 to -2.94, p < 0.00001) at peak effect, but the differences were not significant at the end of follow-up. MG-ADL responders were more frequent with efgartigimod than with placebo (risk ratios [RR] = 1.90, 95% CI: 1.40-2.56, p < 0.0001), including among acetylcholine receptor (AChR)-Ab+ patients (RR = 2.37, 95% CI: 1.61-3.47, p < 0.0001). The incidence of adverse events did not differ from placebo (RR = 0.93, 95% CI: 0.81-1.07, p = 0.29). Certainty of evidence was moderate for peak-effect, responder, and safety outcomes. In uncontrolled real-world studies, responses were observed in AChR-Ab+ and muscle-specific tyrosine kinase (MuSK)-Ab+ patients (MuSK-Ab+ pooled proportion = 0.781, 95% CI: 0.499-0.927; 18 patients) and corticosteroid doses decreased, but this evidence was of very low certainty. Single-arm estimates showed substantial to considerable heterogeneity (I2 up to 98.8%) and wide 95% prediction intervals, although every contributing study showed improvement in MG-ADL and a reduction in corticosteroid dose. Randomized estimates were unchanged when restricted to the phase 3 ADAPT trial, which contributed 71%-92% of the statistical weight. CONCLUSION: In randomized trials, efgartigimod produces clinically meaningful short-term improvement in gMG with an adverse event incidence comparable to placebo. Because the benefit was not maintained at the end of follow-up, cyclical, individualized retreatment is likely required. Real-world data suggest benefit across serological subtypes and a corticosteroid-sparing effect; however, these uncontrolled estimates were heterogeneous and of very low certainty, and larger, longer term controlled studies, ideally conducted independently of the manufacturer, are needed to confirm these findings.

English
Safety and Efficacy of Efgartigimod for Generalized Myasthenia Gravis: A Systematic Review and Meta-Analysis.
内容仅供参考,不构成诊疗建议,不能替代执业医师的诊断。

← 返回元界